ImpediMed Limited (IPDQF) Shareholder/Analyst Call Prepared Remarks Transcript

Key event: leadership transition — Erik Anderson commences as ImpediMed CEO on April 7, 2026. Reimbursement coverage for the company’s BCRL offering now reaches 93% of covered U.S. lives, supporting the board’s view that the next growth phase will be driven by enhanced U.S. commercial execution. The SOZO platform’s addressable market has expanded with two new clinical indications (body composition/weight management and fluid status/heart health), and management’s mandate is to convert broad reimbursement access into accelerated revenue growth.

Analysis

The board-driven mandate to accelerate commercial execution implies the next 6–18 months will be dominated by sales-force productivity metrics (install-to-revenue conversion, utilization per device, retention by clinic type) rather than R&D milestones. If the company can raise utilization from low-single digits to mid-teen percentages within a year in high-frequency touchpoints (weight-management and cardiology clinics), revenue can compound quickly without proportional increases in hardware manufacturing — a high operating-leverage outcome that the market often underprices in small-cap medtech.

Second-order beneficiaries include third-party service providers that handle clinic-level billing and device integration (software partners, managed services) who will see recurring contract growth as devices move from single-use diagnostic to continuous-monitoring workflows. Conversely, incumbent manual assessment pathways and low-cost consumer scales risk losing referrals, pressuring smaller, non-differentiated device vendors and driving consolidation in the outpatient device supplier channel over 12–36 months.

Tail risks center on execution missteps: a sales-force reset, slower-than-expected clinic adoption, or a payer churn episode that would reverse pricing power and make the installed base a lower-margin SaaS-like business. Near-term catalysts to watch are sequential install growth, changes in average revenue per clinic, and any material enterprise agreements with large health systems or national MSK/cardiac service lines — these are the binary events that will re-rate the stock trajectory within quarters rather than years.

Key Decisions for Investors

• Long concentrated position in IPDQF (size 1–2% of fund NAV) with a 12–18 month horizon. Entry: accumulate on any pullback or weakness into alpha events (quarterly installs or major payer/health-system announcement). Risk/reward: target 100% upside if utilization ramps and ARR growth accelerates; downside ~50–60% if execution stalls — employ a 30% stop on initial leg.
• Event-driven call-spread (if liquid) or long-dated OTM calls on IPDQF as a lower-cost alternative (12–18 month tenor). Structure: buy 1Y call / sell higher-strike call to cap cost, aiming for 3:1 reward-to-cost if sequential instal/ARR beats occur in next 3–6 quarters. Allocate no more than 0.5% NAV due to liquidity risk.
• Paired trade to hedge sector beta: long IPDQF (1%) + short IHI (0.5%) to isolate execution and adoption upside vs. broad med-device cyclicality over 6–12 months. This reduces exposure to macro-driven device spending swings while keeping directional exposure to company-specific commercialization progress.
• Catalyst monitoring and stop rules: set alerts for (1) monthly/quarterly install growth >15% QoQ, (2) any national health-system contracts, and (3) negative payer developments. Take 40% profits on the long leg once utilization metrics demonstrate sustained inflection across two consecutive quarters; widen stops if a material enterprise deal is announced.